Expedited Drug Journeys in 2026:
From Designation to Development and Approval
How leading therapies are progressing across accelerated regulatory pathways
Alixorexton
Mechanism of Action: Orexin receptor type 2 agonists Drug Class: G-protein-coupled receptor Originator: Alkermes Indication: Narcolepsy Type 1
Expedited designation: Granted Breakthrough Therapy designation on January 6, 2026
Breakthrough Therapy Designation for Alixorexton:
Advancing a First-in-Class Orexin-Based Approach for Narcolepsy Type 1
- Unmet clinical need identified: Narcolepsy Type 1 is a severe neurological disorder driven by orexin deficiency, with current therapies mainly addressing symptoms rather than the underlying cause.
- Novel therapeutic concept: Alixorexton, an investigational oral orexin 2 receptor agonist, was developed to restore orexin signaling and directly target disease biology.
- Early clinical promise: Initial studies showed meaningful improvements in excessive daytime sleepiness and sleep-attack control, suggesting potential for a significant advance over existing treatments.
- Regulatory evaluation for expedited pathway: The US FDA reviewed preliminary clinical evidence indicating substantial improvement in patient outcomes compared with available therapies for a serious condition.
- Breakthrough Therapy designation granted: Based on this evidence, Alixorexton received Breakthrough Therapy Designation, enabling closer FDA guidance and an accelerated development pathway to potentially bring the therapy to patients sooner.
Calderasib (MK-1084)
Mechanism of Action: KRAS protein inhibitors Drug Class: Small molecules Originator: Merck Sharp & Dohme Corp. Indication: Metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC)
Expedited designation: Granted Breakthrough Therapy designation on May 29, 2026
Breakthrough Therapy Designation for Calderasib (MK-1084):
Advancing Targeted Treatment in Newly Diagnosed KRAS G12C-Mutant NSCLC
- High unmet need in lung cancer: Newly diagnosed metastatic KRAS G12C-mutant NSCLC represents a difficult-to-treat population with limited targeted first-line options and poor long-term outcomes.
- Targeted therapeutic innovation: Calderasib (MK-1084) is an investigational KRAS G12C inhibitor designed to selectively block a key oncogenic driver responsible for tumor growth and progression.
- Early clinical evidence of benefit: Preliminary studies indicated meaningful anti-tumor activity, including tumor response and disease control, suggesting potential improvement over existing treatment approaches in this setting.
- Regulatory assessment for expedited pathway: The US FDA evaluated the available clinical data and determined that the therapy demonstrated the potential for substantial improvement in outcomes for a serious condition.
- Breakthrough Therapy designation granted: Based on this evidence, Calderasib (MK-1084) received Breakthrough Therapy Designation, enabling intensified FDA engagement and an accelerated development pathway to support faster advancement for patients with KRAS G12C-mutant NSCLC.
Pivekimab sunirine (Decnupaz)
Mechanism of Action: Alkylating agents Drug Class: Monoclonal antibodies Originator: ImmunoGen Indication: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Expedited designation: Received Accelerated Approval on May 27, 2026
Accelerated Approval of Decnupaz:
A CD123-Targeted Advance for Ultra-Rare BPDCN
- Severe unmet need in a rare cancer: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an ultra-rare, aggressive hematologic malignancy with limited effective treatment options and poor prognosis.
- Targeted therapeutic strategy: Decnupaz (pivekimab sunirine-pvzy) is a CD123-targeted antibody-drug conjugate designed to selectively deliver cytotoxic activity to malignant BPDCN cells expressing CD123.
- Clinical evidence supporting approval: Clinical studies demonstrated meaningful anti-tumor responses in a difficult-to-treat population, supporting its potential clinical benefit in BPDCN.
- Regulatory pathway for expedited access: Given the rarity and severity of BPDCN and the promising clinical data, the US FDA evaluated the therapy under the Accelerated Approval pathway, which allows earlier approval based on surrogate endpoints.
- Accelerated Approval granted: Decnupaz received Accelerated Approval, providing a critical targeted treatment option for patients with BPDCN while confirmatory studies continue to verify long-term clinical benefit.
